XML 32 R30.htm IDEA: XBRL DOCUMENT
v3.19.3

Concentration of credit risk (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2019
Concentration of credit risk |
Schedule of concentration of credit risk related to collaborative partners | In December 2009, we entered into a license, development and commercialization agreement with Lilly. In November 2009, we entered into a collaboration and license agreement with Novartis. In December 2018, we entered into a research collaboration and licensing agreement with Innovent Biologics, Inc. (“Innovent”). In July 2019, we entered into a collaboration and license agreement with Zai Lab (Shanghai) Co., Ltd., a subsidiary of Zai Lab Limited (collectively, “Zai Lab”). The concentration of credit risk related to our collaborative partners is as follows:
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Percentage of Total | ​ | Percentage of Total | ​
​ | ​ | Milestone and Contract Revenues for the | ​ | Milestone and Contract Revenues for the | ​
​ | ​ | Three Months Ended | ​ | Nine Months Ended | ​
​ | ​ | September 30, | ​ | September 30, | ​
​ |  | 2019 |  | 2018 |  | ​ | 2019 |  | 2018 |  |
Collaboration Partner A |  | — | % | — | % |  | — | % | — | % | ​
Collaboration Partner B |  | — | % | 100 | % | ​ | — | % | 100 | % | ​
Collaboration Partner C | ​ | — | % | — | % | ​ | 77 | % | — | % | ​
Collaboration Partner D |  | 100 | % | — | % |  | 23 | % | — | % | ​
Schedule of concentration of credit risk related to specialty pharmacy customers | In November 2011, we began commercialization and distribution of JAKAFI to a number of customers. Our product revenues are concentrated in a number of these customers. The concentration of credit risk related to our JAKAFI product revenues is as follows:
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Percentage of Total Net | ​ | Percentage of Total Net | ​
​ | ​ | Product Revenues for the | ​ | Product Revenues for the | ​
​ | ​ | Three Months Ended | ​ | Nine Months Ended | ​
​ | ​ | September 30, | ​ | September 30, | ​
​ |  | 2019 |  | 2018 |  | ​ | 2019 |  | 2018 |  |
Customer A |  | 20 | % | 19 | % |  | 19 | % | 20 | % | ​
Customer B |  | 14 | % | 12 | % |  | 14 | % | 13 | % | ​
Customer C |  | 16 | % | 16 | % |  | 16 | % | 15 | % | ​
Customer D |  | 11 | % | 12 | % |  | 12 | % | 11 | % | ​

X
- Definition Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark, related to the collaborative partners. + References No definition available. + Details
Name: | incy_SchedulesOfConcentrationOfRiskByRiskFactorRelatedToCollaborativePartnersTableTextBlock
Namespace Prefix: | incy_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark, related to the specialty pharmaceutical customers. + References No definition available. + Details
Name: | incy_SchedulesOfConcentrationOfRiskByRiskFactorRelatedToSpecialtyPharmaceuticalCustomersTableTextBlock
Namespace Prefix: | incy_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RisksAndUncertaintiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration